API | atoltivimab

atoltivimab (Inmazeb) Report issue

Biologics mAb Orphan Drug ^FDA Approved ^FDA First in Class Breakthrough Therapy ^FDA

AACT

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
atoltivimab

More Chemistry

Pharmacology

Mechanisms of Action:
- Envelope glycoprotein (Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus)) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Combination drugs

inmazeb ( atoltivimab (Inmazeb), maftivimab (Inmazeb), odesivimab (Inmazeb) - other name: atoltivimab, maftivimab, and odesivimab-ebgn )

regn3470

Organizations (3)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (1)

Hemorrhagic Fever, Ebola (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Healthy Volunteers (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue